Abstract: Objectives: Disorders of consciousness (DoC)-that is, unresponsive wakefulness syndrome/ vegetative state and minimally conscious state-are debilitating conditions for which no reliable markers of consciousness recovery have yet been identified. Evidence points to the GABAergic system being altered in DoC, making it a potential target as such a marker. Experimental design: In our preliminary study, we used [ 11 C]Flumazenil positron emission tomography to establish global GABA A receptor binding potential values and the local-to-global (LTG) ratio of these for specific regions. These values were then compared between DoC patients and healthy controls. In addition, they were correlated with behavioral improvements for the patients between the time of scanning and 3 months later. Functional magnetic resonance imaging resting-state functional connectivity was also calculated Additional Supporting Information may be found in the online version of this article. and the same comparisons made. Principal observations: lobal GABA A receptor binding was reduced in DoC, as was the LTG ratio in specifically the supragenual anterior cingulate. Both of these measures correlated with behavioral improvement after 3 months. In contrast to these measures of GABA A receptor binding, functional connectivity did not correlate with behavioral improvement. Conclusions: Our preliminary findings point toward GABA A receptor binding being a marker of consciousness recovery in DoC. Hum Brain Mapp 00:000-000, 2015.
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INTRODUCTION
Unresponsive wakefulness syndrome (UWS; formerly known as vegetative state) and minimally conscious state (MCS) are debilitating neurological conditions characterized as disorders of consciousness (DoC). For patients with DoC, early prognosis and therapy are crucial but markers of recovery are presently lacking.
A number of lines of evidence suggest that the GABAergic system could be a possible target for identifying such markers. First, GABAergic substances such as Zolpidem, a GABA A receptor agonist [Salva and Costa, 1995] , appear to be therapeutically efficacious in a subset of UWS and MCS patients Ciurleo et al., 2013; Clauss, 2011; Pistoia et al., 2010; Rodriguez-Rojas et al., 2013; . Second, an early positron emission tomography (PET) study showed reductions in GABA A receptors across the whole brain in nine patients with UWS [Rudolf et al., 2000] . Unfortunately, this study did not address specific regional deficits or recovery prognosis [Laureys et al., 2000] and has not been followed up in any subsequent investigations of GABA A receptors in DoC.
Recent studies have identified altered resting-state functional magnetic resonance imaging (fMRI) activity in various brain networks in patients with DoC, including the salience network (SN), the default-mode network (DMN), and the executive-control network (ECN) [Crone et al., 2013; Demertzi et al., 2014; Qin et al., 2010; Thonnard et al., 2013] . These networks, therefore, represent plausible targets to focus any investigation of GABA A receptors on. The SN may be of particular interest as fMRI activity levels in a subcomponent of that network-the supragenual anterior cingulate cortex (SACC)-induced by the presentation of the patient's name predicted clinical outcomes in DoC [Qin et al., 2010] . In addition, Zolpidem administration was seen to increase activity within the ACC (and orbitofrontal cortices), with concurrent transient improvements in motor and cognitive performance in one patient with akinetic mutism [Brefel-Courbon et al., 2007] . Zolpidem administration has also been shown to increase metabolism (as measured with [18F]flurodeoxyglucose PET) in the mesiofrontal and dorsolateral prefrontal cortices in three MCS patients . All three patients recovered functional communication after Zolpidem administration, highlighting the potential of the GABAergic system as a prognostic marker.
Given the potential importance of GABAergic changes in DoC, one might hypothesize that measures of GABA A receptors in the brain, and in particular in the ACC, can predict recovery in DoC. To test this, we measured GABA A receptor binding using [ 11 C]flumazenil PET, along with resting-state fMRI. Although the available sample size (n 5 12 UWS and MCS) makes this study preliminary, this multimodal approach is unique in DoC patients.
METHODS

Participants
Seventeen patients with DoC (11 UWS and 6 MCS) were recruited. None were taking benzodiazepines at the time of scanning, nor in the 3 months prior [Guadagno et al., 2008] . Five patients (four UWS, one MCS) who required sputum aspiration during the PET scan were excluded from the analysis, leaving 12 DoC patients (seven UWS, five MCS; four female; mean age 5 45.6 years [63.3 SD]; age range 5 23-61 years; time post injury range 5 36-233 days; see Table I for patient details).
Diagnosis of UWS or MCS was made according to the Coma Recovery Scale-Revised (CSR-R) [Giacino et al., 2004] by an experienced physician (XW) who was not involved in the analysis of the data. The CRS-R comprises six subscales addressing auditory, visual, motor, oromotor/verbal, communication, and arousal components, reflecting the level of consciousness in the patient's behavior. Patients were assessed on the day before the PET session and reassessed immediately prior to the PET scan (T0). Importantly, the two assessments showed consistent results for all patients. All patients were then reassessed 3 months after PET scanning (T1). This reassessment was based on CRS-R scores from two separate examinations within 1 week of each other (giving consistent scores for all patients). The difference between CSR-R scores at T1 and T0 was taken as a measure of behavioral change for the patients (i.e., T1 minus T0, where a positive score represents a behavioral improvement). Three patients who showed behavioral improvements at T1 were rescanned; however, the data from only one of these patients were r Qin et al. r r 2 r usable as the other two patients felt discomfort in the scanner and so could not complete the data acquisition.
Nine healthy volunteers participated in the study (four female; mean age 5 35.6 years [64.06 SD]; age range 5 23-55 years). There was no age difference between patients and healthy controls (HC) (P 5 0.07). None of the healthy participants had a history of neurological or psychiatric disorders or were taking medication. Two of these HC were rescanned 3 months after their initial one (i.e., at T1). Written informed consent was obtained from the healthy participants and the legal representatives of the patients. The study was approved by the Ethics Committees of the Shanghai Huashan Hospital, Fudan University, Shanghai, China.
GABA A Receptor Binding Potentials
PET imaging with radiolabeled flumazenil (FMZ), a benzodiazepine antagonist that binds at the GABA A receptor benzodiazepine site, has been widely used to measure GABA A receptor density in vivo in humans [Frey et al., 1991] . Whole-brain [11C]FMZ data was obtained using a Siemens Biograph 64 positron emission tomography-computed tomography (PET/CT). Head movement was minimized with a head-restraining adhesive band. A CT scan was acquired for attenuation correction, followed by an intravenous tracer injection (over 60 s) of 380.3 MBq (670.4 SD) of [11C]FMZ for HC and 386.0 MBq (670.0 SD) of [11C]FMZ for patients. Doses did not differ between patients and healthy subjects (independent two-sample ttest, t 5 1.86, P 5 0.85). Participants were instructed to close their eyes and remain awake during scanning. To ensure that healthy participants remained awake during scanning, they were asked to raise their hand every 10 min. Similar prompts were given to patients, as has been done in previous studies Vanhaudenhuyse et al., 2010] .
Three-dimensional (3D) list-mode data were acquired for a period of 60 min and then binned into a series of 26 frames consisting of six 30-s frames followed by seven 60-s, five 120-s, and eight 300-s frames [Salmi et al., 2008] . A linear 3D filtered backprojection (3D-FBP) was preferred for the modeling analysis of [11C]FMZ kinetics [van Velden et al., 2009] with full accounting for scatter, random coincidences, attenuation, decay dead-time correction, and frame-based motion correction [Costes et al., 2009] . The inplane reconstructed resolution was 6-mm full-width at half-maximum. The images used had a voxel size of 1.22 3 1.22 3 1.22 mm 3 (256 3 256 3 207 voxels). We used a subset from 10 to 60 min to calculate the binding potential (BP ND ) according to the Logan plot method [Logan et al., 1996] . The bilateral cerebellar white matter was used as the reference as it generally has less damage than other brain regions in DoC patients [Qin et al., 2012; Rudolf et al., 2000] (see Supporting Information Fig. 1 for patient cerebellar structural images). To define this reference region, each person's T1-weighted 3D anatomical MRI image (see MRI Data Acquisition and Processing for details) was segmented using the FAST tool from FSL to give a white matter map and then aligned to their binding potential image. The white matter maps were masked with the cerebellar mask from the Harvard Oxford atlas (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases), thresholded at 0.9 (from a range of 0 to 1), and binarized. The resulting cerebellar white matter mask was then eroded by one voxel to generate the final individual reference region.
Regions of Interest
Using the AFNI template (TT_desai_dk_mpm) [Desikan et al., 2006] , we defined regions of interest (ROIs) corresponding to the functional networks identified in previous studies as showing altered activity in DoC [Crone et al., 2013; Demertzi et al., 2014; Qin et al., 2010; Thonnard et al., 2013] . These were the SN, the DMN, the ECN, and the auditory network (AN). The SN ROI was composed of the SACC and anterior insula (AI); the DMN of the posterior cingulate cortex (PCC), perigenual anterior cingulate cortex (PACC), and bilateral temperoparietal junction (TPJ); and the ECN of the bilateral dorsolateral prefrontal cortex (DLPFC), bilateral inferior parietal lobe (IPL), and precuneus (PreCu). The AN included the bilateral auditory cortex. As the AFNI template does not include a separate AI mask, we created the insula ROI by combining the ventral and dorsal AI regions identified by Deen et al. [2011] . To obtain the individual ROIs for each participant, the BP ND map of each participant (HC and patients) was normalized to a standard T1-weighted template, as described previously [Duncan et al., 2013] . The inverse of these normalization parameters were then used to warp the relevant ROIs from the AFNI template onto the nonnormalized individual BP ND maps for healthy and patient groups [Qin et al., 2010] .
Calculating BP ND in Gray Matter
As the GABA A receptor is predominantly located in the gray rather than white matter [Heiss and Herholz, 2006] , and because BP ND is known to correlate with gray matter density [Duncan et al., 2013] , it is necessary to limit the ROIs to gray matter only. Were the whole ROI (including both gray and white matter) to be used, any results could be attributed to differences in the volume of gray matter within the particular region between participants rather than differences in GABA A receptors per se. We, therefore, calculated BP ND in gray matter alone as follows: MRI anatomical images were segmented to give gray matter maps. These were thresholded at 0.5 to create a mask of highprobability gray matter voxels and converted into PET space. To remove additional nontissue voxels, we also thresholded the BP ND maps at 0.5 and applied this mask to the gray matter mask (see Supporting Information Fig.  1 for an example mask). Network ROIs in PET space created previously were then restricted according to these gray matter masks. Finally, the mean GABA A receptor BP ND within each ROI and within the gray matter as a whole was calculated. To correct for unspecific gray matter volume effects, the mean GABA A BP ND for each region was divided by the mean gray matter proportion of that region [Qin et al., 2012] . This was done for each network ROI and for the total gray matter region.
Statistical Analysis for PET
For whole-brain BP ND values difference between DoC and HC, the effect of age and FMZ dose were removed from the whole-brain BP ND values using linear regression. The resulting residuals for the whole-brain BP ND values were then compared between DoC patients and HC through a Mann-Whitney U test. For the relationship between whole-brain BP ND and CRS-R scores, the effect of participant age, the dose of FMZ, and the length of time since the patient's injury were removed from the wholebrain BP ND values and CRS-R scores through linear regression. The Spearman's correlations between the resulting residuals for the global BP ND values and both the CRS-R scores at T0 and the behavioral change (i.e., CRS-R T1-T0) were then calculated. Finally, as the CRS-R is not a purely quantitative measure but also requires particular patterns of scoring for different diagnoses, we further tested the association between BP ND and behavioral improvement by first classifying a patient as improved or not from whether their CRS-R score was higher at T1 than at T0. They were then classified as having a global BP ND value within or outwith two standard deviations of the mean for healthy participants. The correlation between these classifications was then established through a Fisher's exact test. This classification approach has the additional advantage of potentially providing information that is directly clinically relevant.
Having investigated whole-brain BP ND values, we then focused on these values for particular networks. For this, the BP ND local-to-global (LTG) ratio was calculated for each network and this value used in the subsequent calculations [Qin et al., 2012] . This value represents the mean BP ND in each network divided by the average BP ND of the whole r Qin et al. r r 4 r brain, allowing us to measure potentially differential changes in specific regions relative to the global value and so increase specificity by eliminating global effects. This division may also eliminate the potential effect of age, FMZ dose, and length of time since injury on GABA A BP DN values [Yamauchi et al., 2005] . Differences between patient and control LTG ratios were tested through Mann-Whitney U tests. Bonferroni correction for the four networks was done in each of these comparisons (SN, DMN, ECN , and AN) (P < 0.05; P < 0.0125 uncorrected). Finally, following the network level analysis, we investigated the various constitutive brain regions within any of the networks that showed a difference in FMZ BP ND LTG ratio between patients and controls. We repeated the same analysis in each subregion as was done for the network as a whole. In addition, Spearman correlations between network LTG ratios and CRS-R scores at T0 and the behavioral change (T1-T0) were also calculated. Within the specific network, Bonferroni correction was done based on the number of brain regions constituting it.
MRI Data Acquisition and Processing
Of the 12 patients with usable PET data, 10 also had fMRI data available. All HC had usable fMRI data. MR images were acquired on a Siemens 3 Tesla scanner. Functional images were acquired using a T2*-weighted echo-planar imaging sequence (repetition time/echo time/h 5 2,000 ms/35 ms/908, field of view 5 256 mm, matrix 5 64 3 64, slice thickness 5 4 mm, gap 5 0 mm, 33 slices, 200 volumes). A T1-weighted high-resolution 3D whole-brain image was also obtained (repetition time 5 2300 ms, echo time 5 2.98 ms, Matrix 5 256 3 256, slice thickness 5 1 mm). fMRI imaging was done randomly either before or after the PET scan (mean duration between scans 5 8.1 days 6 8.9 SD). The diagnoses remained the same for all patients during both fMRI and PET scanning. All the participants (HC and patients) were instructed to close their eyes and remain awake during scanning. Unfortunately, due to their condition, it was not possible to entirely ensure wakefulness in the patients .
The data were processed using the AFNI and FSL software packages. The first two volumes were discarded. The data then underwent a preprocessing procedure that included slice-timing correction, two-and threedimensional head-motion corrections, masking for the removal of the skull, and spatial smoothing using a 6-mm full-width at half-maximum kernel. Time-series were then normalized by computing the ratio of the signal in each voxel and each time point to the mean across all time points, multiplied by 100. The estimated head motion and the mean time-series from the white matter and the cerebrospinal fluid (where these regions were defined using thresholds of 0.99 for each tissue type) were regressed out of the data [Saad et al., 2012] . The data were band-pass filtered, reserving signals between 0.01 and 0.08 Hz [Song et al., 2011] .
As minor group differences in head motion can cause spurious differences in imaging measures between them [Power et al., 2012; Van Dijk et al., 2012] , a rigorous approach to head-motion correction was adopted. Motion was quantified as the absolute Euclidean distance moved from the head position in the prior time point, as calculated from the six rigid-body motion parameters. Where there was movement of more than 0.5 mm between time points, the relevant volume, plus the preceding and subsequent volumes, was removed from the dataset [Huang et al., 2013] . To obtain reliable functional connectivity values, participants with less than 3 min of data remaining following this procedure were excluded [Yan et al., 2013] . This resulted in the exclusion of three patients (from 10).
We explored the resting-state functional connectivity between the different regions that compose the SN (the AI and the SACC). This network was chosen for the analysis as it was the only one that shows a difference in FMZ BP ND LTG ratio between patients and controls. Considering the similar time course in the corresponding regions between the two hemispheres, and to reduce physiological and scanner noise, we collapsed the time courses from the bilateral AI. Pearson's correlation coefficient between the time-series of AI and SACC was calculated and converted to normally distributed Z-values using Fisher's Z transformation. These Z-values were compared between patients and controls using a Mann-Whitney U test. Finally, we calculated the Spearman correlation between functional connectivity and CRS-R scores at T0, as well as the behavioral change (CRS-R T1 -T0). The significance level was set at P < 0.05.
RESULTS
Behavioral and Clinical Data
Five patients showed clear behavioral improvements between T0 and T1 (MCS 1, 4, 5 and UWS 6, 7). MCS 1, 5 and UWS 6, 7 could perform verbal communication 3 months after the initial assessment (Table I, plus Supporting Information Tables I and II) . Although MCS 4 was unable to verbally communicate in a stable fashion, they were able to say intelligible words, pursue a visual stimulus, and localize noxious stimulation at T1 (they was unable to do these at T0). The remaining patients did not show any behavioral changes between T0 and T1.
Whole-Brain GABA A Receptor BP ND Mean whole-brain GABA A receptor BP ND values were significantly lower (37% reduction) in DoC patients than in HC (P 5 0.001) (Fig. 1B) . There was a positive correlation between GABA A receptor BP ND and behavioral change (CRS-R T1-T0) (rho 5 0.62, 95% confidence interval (Fig. 1E) . All patients who did not improve between T0 and T1 showed lower GABA A receptor BP ND than those who had an improvement in their level of consciousness.
Network GABA A Receptor BP ND
Absolute GABA A receptor BP ND in each of the networks studied (SN, DMN, ECN, and AN) was lower in patients than in HC (Supporting Information Fig. 3 ). Taking this global reduction into account through LTG ratios, there was a relative reduction in GABA A receptor BP ND values between patients and HC in the SN specifically (P 5 0.024 corrected; P 5 0.006 uncorrected) (Fig. 2) . There was no reduction in LTG ratios in the other networks studied. Within the patient group, there was no different in LTG ratios between UWS and MCS patients (Supporting Information Fig. 4 and 5) .
GABA A Receptor BP ND in the SN
With only the SN showing reduced LTG ratios, we investigated this network further by dividing it into its constituent regions-the SACC and the AI. BP ND LTG ratios were significantly reduced in the SACC in patients with DoC when compared with HC (P 5 0.004 corrected; P 5 0.002 uncorrected), as were LTG ratios in the AI (P 5 0.036 corrected; P 5 0.018 uncorrected) (Fig. 3B) .
We then tested the correlation between LTG ratios and behavioral change (CRS-R T1 minus T0) in each region. The LTG in the SACC was significantly correlated with behavioral change (rho 5 0.81, 95% C.I. 5 0.48 2 0.95, P 5 0.004 corrected, P 5 0.002 uncorrected) (Fig. 3C) , while no correlation was seen in the AI. However, the relationship between LTG ratio in the SACC (whether LTG ratio lie within 2 SD of HC mean) and behavioral improvement classification (CRS-R T1 > T0) was not significant (Fisher's test, P 5 0.08) (Fig. 3D) .
To establish the specificity of the SACC, we also investigated other areas of the cingulate cortex (Supporting Information Fig. 6 ). A reduction in LTG ratios in DoC patients was additionally seen in the perigenual anterior cingulate (PACC). There was no change in the mid-cingulate cortex and the PCC. However, there was no correlation between LTG ratios of the PACC and CRS-R scores at T0 or with behavioral change (T1-T0).
BP ND After Behavioral Improvement
UWS6 was scanned at both T0 and T1. Both their global BP ND and LTG ratio in the SACC were located within the range of the HC at T1 (they were also in this range at T0). Two HC also underwent a second scan 3 months after their first. There were no differences in their global BP ND values between these times (Supporting Information  Fig. 7) . LTG GABA A BP ND ratios (mean 6 SE) for networks studied in DoC patients and HC. The upper panel shows the regions that make up each network. * denotes a significant difference (P < 0.05, corrected). AC 5 auditory cortex, AI 5 anterior insula, DLPFC 5 dorsolateral prefrontal cortex, IPL 5 inferior parietal lobe, PACC 5 perigenual anterior cingulate cortex, PCC 5 posterior cingulate cortex, PreCu 5 precuneus, SACC 5 supragenual anterior cingulate cortex, TPJ 5 temperoparietal junction. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] r GABA A Receptor Predicts Consciousness r r 7 r
Functional Connectivity in the SN
Functional connectivity between the SACC and AI (the subregions of the SN) was reduced in patients with DoC, as compared with HC (P 5 0.016) (Fig. 4) . However, unlike with GABA A receptor BP ND , functional connectivity did not correlate with patients' CRS-R scores at T0, nor with their behavioral change (T1-T0)
Although outwith the focus of our analysis, for completeness, we also looked at functional connectivity in the other networks. Functional connectivity was reduced in each of the DMN, ECN, and AN in DoC patients. Subdividing these networks into their constituent ROIs, in the DMN, functional connectivity was reduced between the PACC and PCC; while in the ECN, functional connectivity was reduced between the DLPFC and PreCu only (Supporting Information Fig. 8 ).
DISCUSSION
Our preliminary study reports major GABA A receptor deficits in the whole brain, in the SACC in particular, and in DoC. These GABAergic alterations can predict recovery after 3 months. The potentially special role of the SACC was further supported by alterations in resting-state functional connectivity, as measured with fMRI, in the same patients. Although preliminary, our results demonstrate for the first time that GABA A receptor BP ND can be linked to outcomes in DoC. Our findings may bear important implications for the understanding of altered GABAergic mechanisms in DoC and point toward use of FMZ PET as a prognostic marker in UWS and MCS.
Global Deficits in GABA A Receptors and GABAergic Therapy
Our study replicated earlier findings of reduced wholebrain GABA A receptor binding in UWS [Rudolf et al., 2000] and extended them by providing a link to outcomes. Previous studies suggested that GABA A receptor changes could reflect irreversible neuronal damage [Heiss, 2012] . This may provide one potential interpretation to the prognostic value of whole-brain GABA A receptor BP ND . This is supported by the data from the patient scanned at both T0 and T1, where there is no difference in BP ND before and after recovery of consciousness.
GABAergic drugs such as Zolpidem have been shown to restore consciousness in some DoC patients [Ciurleo et al., 2013; Clauss, 2010; Clauss, 2011; Pistoia et al., 2010] . The mechanism of this effect is unknown but may be related to the hypersensitive state of GABA receptors in neurodormant cells [Clauss and Nel, 2006] . It is hypothesized that after brain injury GABA receptors become hypersensitive so that decreased GABA can suppress cellular metabolism and maintain a dormant state. With the introduction of Zolpidem, GABA receptor function may be returned to normal, ceasing the dormant state. Based on our findings, one would predict that the subset of patients who are reactive to Zolpidem [Whyte et al., 2014] might show particularly high degrees of GABA A receptor binding when compared with those that do not [Ciurleo et al., 2013; Du et al., 2014; Singh et al., 2008] .
SN and SACC in DoC
In addition to whole-brain changes, we also showed that there is a reduction in the LTG ratio of GABA A receptor BP ND in the SN, specifically in the SACC. As with wholebrain BP ND , the SACC LTG ratio was correlated with behavioral improvement after 3 months. The SN, and particularly the SACC, has previously been demonstrated to be associated with consciousness [Crone et al., 2013; Devinsky et al., 1995; Qin et al., 2010] . Moreover, the "mesocircuit hypothesis" for the recovery of consciousness claims a central role for the connection between thalamus and anterior frontal cortex (especially the SACC) in recovery of consciousness [Schiff, 2010] . Our results provide support for this hypothesis by showing a particular relationship between SACC BP ND and the recovery of consciousness.
Functional connectivity between the SACC and the AI was also reduced in patients with DoC. Unlike with SACC BP ND , however, the degree of connectivity was not correlated with the level of consciousness at T1. This suggests that there may be a dissociation in the role that SACC GABA A receptor binding and functional connectivity play in supporting consciousness. If we consider GABA A receptor BP ND to reflect neuronal integrity [Heiss, 2012] , then, this contrasts with functional connectivity, which instead reflects neural activity synchronization between regions. In DoC patients, the remaining tissue may suffer from a major decrease in metabolism [Laureys and Schiff, 2012; Northoff, 2014; Shulman et al., 2003] . Such a metabolic decrease may put neurons into the aforementioned "dormant state" which may in turn down-modulate functional connectivity [Ciurleo et al., 2013; Du et al., 2014] .
Besides the SN, previous studies have also shown reduced functional connectivity within the DMN, ECN, and AN in DoC patients when compared with HC . This is consistent with our findings of significantly reduced functional connectivity (Supporting Information Fig. 8 ) and BP ND in these networks (Supporting Information Fig. 3 ). The reduction in BP ND would appear to reflect a generalized or global effect, as the difference between DoC patients and controls is lost following normalization of the values (i.e., the calculation of the LTG ratio). Such global GABAergic alterations may be linked to the reductions in functional connectivity observed across the networks. When considering the LTG ratio, significant reductions in GABA A BP ND remained only in the SACC (and not in the other regions and networks). This suggests that GABA A BP ND in the SACC is reduced in a regionally specific manner not shared by the rest of the brain. Importantly, it is this region that shows a particular relevance for predicting the recovery of consciousness.
Limitations and Future Directions
The modestly sized and clinically somewhat heterogeneous sample must be mentioned. Although the current data must be considered preliminary, the results are consistent with a prior study showing reduced GABA A receptor density in nine acute DoC patients [Rudolf et al., 2000] . Furthermore, FMZ PET is a well-developed method that gives stable and reliable results [Salmi et al., 2008] . However, it is necessary to replicate our results in larger and more homogeneous samples. A second limitation is that only one patient could be scanned successfully after recovery. This leaves open interesting questions as to how GABA A BP ND may change in line with behavioral improvement. Similarly, the rescanning of patients who do not improve would provide information as to whether irreversible brain damage in these patients remains unchanged or gets worse. Future studies may seek to include a brain-lesioned group who retain full consciousness to act as a control for the effect of focal brain injury itself. Moreover, it may be advisable to investigate recovery over periods longer than 3 months. Finally, fluorodeoxyglucose (FDG) PET values have previously been shown to be correlated with [
11 C]flumazenil PET [Rudolf et al., 2002] . FDG is a more commonly used tracer in DoC patients [Stender et al., 2014] and so it would be interesting to establish if this method can be used in place of FMZ to make clinical outcome predictions by applying an analogous methodology to that described here.
In conclusion, although preliminary, our study demonstrates for the first time that GABA A receptor binding in the whole brain, and in the SACC particularly, predicts behavioral improvement in DoC. This complements recent clinical reports of therapeutic efficacy of the GABAergic drug Zolpidem in these patients.
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